News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

SUNRISE supports tezepelumab in severe OCS-dependent asthma
24 Sep 2026
byAudrey Abella
In the phase III SUNRISE trial, tezepelumab significantly reduces daily maintenance oral corticosteroid (OCS) dose while maintaining asthma control in adults with severe OCS-dependent asthma, despite early study termination and the smaller-than-planned sample size.
24 Sep 2026







